Delivery Order SPE2DB22D2206-SPE2DB25FJA34
- Not listed
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injectors with a firm fixed price ceiling value of $1,501.15 and completion date of July 31, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Imitrex 6 mg/0.5 ml pen injectors with a ceiling value of $1,434.02 and an ultimate completion date of June 2, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreements with the federal government. The product will be delivered to the vendor's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,234.04 to AmerisourceBergen Drug Corp on December 23, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injections. This firm fixed-price contract, with an ultimate completion date of December 24, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made through open competition...
- AmerisourceBergen Drug Corp was awarded a $2,451.26 delivery order by the Defense Logistics Agency (DLA) on August 11, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injector (0.5 mL). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and represents a non-competitive award outside of any set-aside program. The place of performance is located in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate...
- On July 29, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a $2,905.89 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Imitrex 6 mg/0.5 mL pen injectors. This is a non-set-aside contract awarded through open competition, with an ultimate completion date of July 30, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in Conshohocken, PA 19428....
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $3,893.64 on September 23, 2025, for the supply of Imitrex 4 mg/0.5 mL pen injectors with a completion date of September 24, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child contract under AmerisourceBergen's larger procurement vehicle. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a $1,835.70 firm fixed-price delivery order to Amerisourcebergen Drug Corp on January 22, 2026, for the supply of Imitrex 4 mg/0.5 ml pen injectors. This non-competitive delivery order represents a single task order under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award carries an ultimate completion date of January 23, 2026, with...
- The Defense Logistics Agency awarded a $4,211.79 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injectors. This firm fixed price, non-set-aside contract is scheduled for completion by August 1, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation of the company's extensive pharmaceutical supply relationship with the federal...
- The Defense Logistics Agency awarded a $5,869.17 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injectors with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Imitrex (sumatriptan) is a prescription medication used to treat migraine headaches, and this...
- The Defense Logistics Agency awarded a $13,635.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of Imitrex 6 mg/0.5 ml pen injectors. The contract, which carries an ultimate completion date of July 14, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen will perform this work from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJA34Delivery Order
The Defense Logistics Agency (DLA) awarded a $5,576.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injectors (0.5 mL units). This contract is not set-aside and represents a competitively awarded delivery order with an ultimate completion date of July 23, 2025. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal vendor supplying a broad range of medications and medical supplies to military and veteran healthcare systems. The company's extensive federal contract portfolio with the DLA demonstrates its capability to fulfill complex pharmaceutical procurement requirements across multiple therapeutic domains. This particular delivery order for Imitrex, a migraine treatment medication, exemplifies the company's role in supporting the Defense Health Agency and other federal healthcare programs through flexible and competitive contracting mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 7/22/25 |